基于多机构临床试验数据集(JCOG1015A1)的头颈部调强放疗危及器官剂量限制
JCOG1015A1是一项辅助研究,利用JCOG1015中74例接受调强放疗的鼻咽癌患者的个体数据和剂量体积直方图,确定头颈部癌危及器官的剂量限制。研究采用累积发生率法或患病比例评估晚期毒性,并用ROC分析估算预测毒性的最佳DVH截断值。结果显示多数危及器官的剂量限制标准合适,但内耳、咽缩肌和脑干可能需要更严格的剂量限制。
要点
- 脑干D1cc≥55.8 Gy与脊髓炎显著相关,脑D1cc≥72.1 Gy与中枢神经系统坏死显著相关。
- 眼球Dmax≥36.6 Gy与视神经障碍显著相关,同侧内耳Dmean≥44 Gy与听力受损显著相关。
- 对侧腮腺Dmean≥25.8 Gy组2年G2口干患病比例为17%,低于该剂量组为6%。
核心结论
- 本研究中大多数危及器官的剂量限制标准是合适的,但内耳、咽缩肌和脑干可能需要更严格的剂量限制。
研究设计与样本
- JCOG1015A1是JCOG1015的辅助研究,收集74例接受调强放疗的鼻咽癌患者的个体数据和危及器官剂量体积直方图。
主要发现
- 5年累积发生率:G1脊髓炎10%,≥G1中枢神经系统坏死5%,G2视神经障碍2%,≥G2吞咽困难11%,≥G2喉水肿5%,≥G2听力受损26%,≥G2中耳炎34%,≥G1甲状腺功能减退34%。
- 脑干D1cc≥55.8 Gy与脊髓炎显著相关,脑D1cc≥72.1 Gy与中枢神经系统坏死显著相关,眼球Dmax≥36.6 Gy与视神经障碍显著相关,同侧内耳Dmean≥44 Gy与听力受损显著相关。
- 视神经、咽缩肌和甲状腺的DVH参数与毒性发生率呈趋势性关联。
- 2年G2口干患病比例:对侧腮腺Dmean≥25.8 Gy组为17%,低于该剂量组为6%。
关键数值与推荐
- 脑干脊髓炎预测阈值:D1cc≥55.8 Gy。
- 脑中枢神经系统坏死预测阈值:D1cc≥72.1 Gy。
- 眼球视神经障碍预测阈值:Dmax≥36.6 Gy。
- 同侧内耳听力受损预测阈值:Dmean≥44 Gy。
- 对侧腮腺Dmean≥25.8 Gy组2年G2口干患病比例为17%,低于该剂量组为6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: JCOG1015A1 is an ancillary research study to determine the organ-specific dose constraints in head and neck carcinoma treated with intensity-modulated radiation therapy (IMRT) using data from JCOG1015. METHODS: Individual patient data and dose-volume histograms of organs at risk (OAR) were collected from 74 patients with nasopharyngeal carcinoma treated with IMRT who enrolled in JCOG1015. The incidence of late toxicities was evaluated using the cumulative incidence method or prevalence proportion. ROC analysis was used to estimate the optimal DVH cut-off value that predicted toxicities. RESULTS: The 5-year cumulative incidences of Grade (G) 1 myelitis, ≥ G1 central nervous system (CNS) necrosis, G2 optic nerve disorder, ≥ G2 dysphagia, ≥ G2 laryngeal edema, ≥ G2 hearing impaired, ≥ G2 middle ear inflammation, and ≥ G1 hypothyroidism were 10%, 5%, 2%, 11%, 5%, 26%, 34%, and 34%, respectively. Significant associations between DVH parameters and incidences of toxicities were observed in the brainstem for myelitis (D1cc ≥ 55.8 Gy), in the brain for CNS necrosis (D1cc ≥ 72.1 Gy), in the eyeball for optic nerve disorder (Dmax ≥ 36.6 Gy), and in the ipsilateral inner ear for hearing impaired (Dmean ≥ 44 Gy). The optic nerve, pharyngeal constrictor muscle (PCM), and thyroid showed tendencies between DVH parameters and toxicity incidence. The prevalence proportion of G2 xerostomia at 2 years was 17 versus 6% (contralateral parotid gland Dmean ≥ 25.8 Gy vs less). CONCLUSIONS: The dose constraint criteria were appropriate for most OAR in this study, although more strict dose constraints might be necessary for the inner ear, PCM, and brainstem.
引用
- Inada M, Nishimura Y, Ishikura S, et al. Organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using a dataset from a multi-institutional clinical trial (JCOG1015A1). Radiat Oncol. 2022. PMID: 35902868. doi:10.1186/s13014-022-02105-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。